JP4505135B2 - Ｄ２及びｄ３ドーパミンならびに５ｈｔ１ａ及び５ｈｔ２セロトニンのレセプターのリガンドとしての８−アザビシクロ［３．２．１］オクタン−３−メタンアミン誘導体 - Google Patents

Ｄ２及びｄ３ドーパミンならびに５ｈｔ１ａ及び５ｈｔ２セロトニンのレセプターのリガンドとしての８−アザビシクロ［３．２．１］オクタン−３−メタンアミン誘導体 Download PDF

Info

Publication number
JP4505135B2
JP4505135B2 JP2000515897A JP2000515897A JP4505135B2 JP 4505135 B2 JP4505135 B2 JP 4505135B2 JP 2000515897 A JP2000515897 A JP 2000515897A JP 2000515897 A JP2000515897 A JP 2000515897A JP 4505135 B2 JP4505135 B2 JP 4505135B2
Authority
JP
Japan
Prior art keywords
mmol
azabicyclo
dihydro
compound
octane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2000515897A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001519431A (ja
Inventor
マラブ，ブノワ
セヴラン，ミレーユ
ジョルジュ，パスカル
メルリ，ジャン−ピエール
ピレティ，ダニエル ド
ロイ，ジョスリーヌ
マシュニック，ダヴィド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Synthelabo SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9712580A external-priority patent/FR2769628B1/fr
Priority claimed from FR9712583A external-priority patent/FR2769629B1/fr
Application filed by Sanofi Synthelabo SA filed Critical Sanofi Synthelabo SA
Publication of JP2001519431A publication Critical patent/JP2001519431A/ja
Application granted granted Critical
Publication of JP4505135B2 publication Critical patent/JP4505135B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
JP2000515897A 1997-10-09 1998-10-07 Ｄ２及びｄ３ドーパミンならびに５ｈｔ１ａ及び５ｈｔ２セロトニンのレセプターのリガンドとしての８−アザビシクロ［３．２．１］オクタン−３−メタンアミン誘導体 Expired - Fee Related JP4505135B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
FR9712580A FR2769628B1 (fr) 1997-10-09 1997-10-09 Derives de n-(2,3-dihydro-1h-inden-2-yl)-n-propyl-8- azabicyclo[3.2.1.]octane-3-methanamine, leur preparation et leur application en therapeutique
FR9712583A FR2769629B1 (fr) 1997-10-09 1997-10-09 Derives de 8-azabicyclo[3.2.1]octane-3-methanamine, leur preparation et leur application en therapeutique
FR97/12583 1997-10-09
FR97/12580 1997-10-09
PCT/FR1998/002137 WO1999019325A1 (fr) 1997-10-09 1998-10-07 Derives de 8-azabicyclo [3.2.1] octane-3-methanamine en tant que ligands des recepteurs de dopamine d2 et d3 et de serotonine 5ht1a et 5ht2

Publications (2)

Publication Number Publication Date
JP2001519431A JP2001519431A (ja) 2001-10-23
JP4505135B2 true JP4505135B2 (ja) 2010-07-21

Family

ID=26233854

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000515897A Expired - Fee Related JP4505135B2 (ja) 1997-10-09 1998-10-07 Ｄ２及びｄ３ドーパミンならびに５ｈｔ１ａ及び５ｈｔ２セロトニンのレセプターのリガンドとしての８−アザビシクロ［３．２．１］オクタン−３−メタンアミン誘導体

Country Status (31)

Country Link
US (1) US6221879B1 (no)
EP (1) EP1021442B1 (no)
JP (1) JP4505135B2 (no)
KR (1) KR20010015717A (no)
CN (1) CN1140526C (no)
AR (1) AR017300A1 (no)
AT (1) ATE212631T1 (no)
AU (1) AU746935B2 (no)
BG (1) BG64859B1 (no)
BR (1) BR9812752A (no)
CA (1) CA2305468C (no)
CO (1) CO5011097A1 (no)
CZ (1) CZ290679B6 (no)
DE (1) DE69803689T2 (no)
DK (1) DK1021442T3 (no)
EE (1) EE04347B1 (no)
ES (1) ES2171306T3 (no)
HK (1) HK1029108A1 (no)
HU (1) HUP0102086A3 (no)
IL (2) IL135520A0 (no)
NO (1) NO325170B1 (no)
NZ (1) NZ503829A (no)
PL (1) PL186998B1 (no)
PT (1) PT1021442E (no)
RU (1) RU2203281C2 (no)
SI (1) SI1021442T1 (no)
SK (1) SK283080B6 (no)
TR (1) TR200000942T2 (no)
TW (1) TW444014B (no)
UA (1) UA58476C2 (no)
WO (1) WO1999019325A1 (no)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6689806B1 (en) 1999-03-24 2004-02-10 Sugen, Inc. Indolinone compounds as kinase inhibitors
US6878733B1 (en) 1999-11-24 2005-04-12 Sugen, Inc. Formulations for pharmaceutical agents ionizable as free acids or free bases
EP1812389B1 (en) * 2004-10-14 2011-08-17 Abbott GmbH & Co. KG Azabicycloheptyl compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor
US7297704B2 (en) 2005-02-17 2007-11-20 Wyeth Cycloalkyfused indole, benzothiophene, benzofuran and idene derivatives
AU2011225095C1 (en) 2010-03-11 2017-01-19 Sumitomo Dainippon Pharma Co., Ltd. N-Acyl cyclic amine derivative or pharmaceutically acceptable salt thereof
WO2016092546A1 (en) 2014-12-09 2016-06-16 Ezekiel Golan Binge behavior regulators
CN107406370A (zh) 2014-12-09 2017-11-28 以西结·戈兰 酒精饮料替代品
KR102128782B1 (ko) 2018-09-20 2020-07-01 한양대학교 에리카산학협력단 트로페인(Tropane) 알칼로이드 화합물 및 순차적 산화반응을 이용한 이의 제조방법

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL59004A0 (en) 1978-12-30 1980-03-31 Beecham Group Ltd Substituted benzamides their preparation and pharmaceutical compositions containing them
JPS5592384A (en) * 1978-12-30 1980-07-12 Beecham Group Ltd Compound having pharmacological activity
IL61642A0 (en) * 1979-12-20 1981-01-30 Beecham Group Ltd Aniline derivatives,their preparation and pharmalceutical compositions containing them
US4910302A (en) 1988-12-19 1990-03-20 American Home Products Corporation Psychotropic polycyclic imides
FR2659323B1 (fr) * 1990-03-07 1992-06-12 Synthelabo Derives de 4-(aminomethyl) piperidine, leur preparation et leur application en therapeutique.
FR2681320B1 (fr) 1991-09-12 1994-01-14 Synthelabo Derives de n-(4,7dimethoxyindan-2-yl)-1-(phenylcarbonyl)-n-propyl-piperidine-4-methanamine, leur preparation et leur application en therapeutique.
FR2681325B1 (fr) 1991-09-16 1993-12-17 Fabre Medicament Pierre Derives de l'aminomethyl-4 piperidine, leur preparation et leur application en therapeutique.
DE4135474A1 (de) 1991-10-28 1993-04-29 Bayer Ag 2-aminomethyl-chromane
FR2702211B1 (fr) 1993-03-04 1995-06-02 Pf Medicament Nouveaux dérivés de la phénoxy-2 éthylamine, leur préparation et leur application en thérapeutique.

Also Published As

Publication number Publication date
CN1140526C (zh) 2004-03-03
SK5042000A3 (en) 2001-03-12
CZ20001278A3 (cs) 2000-07-12
EE04347B1 (et) 2004-08-16
US6221879B1 (en) 2001-04-24
ATE212631T1 (de) 2002-02-15
UA58476C2 (uk) 2003-08-15
BR9812752A (pt) 2000-08-29
BG64859B1 (bg) 2006-07-31
HK1029108A1 (en) 2001-03-23
NO325170B1 (no) 2008-02-11
AU9446898A (en) 1999-05-03
NZ503829A (en) 2002-03-28
AR017300A1 (es) 2001-09-05
EP1021442A1 (fr) 2000-07-26
DK1021442T3 (da) 2002-05-13
TR200000942T2 (tr) 2000-09-21
BG104309A (en) 2001-05-31
CA2305468C (en) 2007-09-25
PL186998B1 (pl) 2004-04-30
HUP0102086A3 (en) 2002-09-30
CO5011097A1 (es) 2001-02-28
AU746935B2 (en) 2002-05-09
ES2171306T3 (es) 2002-09-01
NO20001810L (no) 2000-06-09
SI1021442T1 (en) 2002-08-31
PL339764A1 (en) 2001-01-02
TW444014B (en) 2001-07-01
CN1281455A (zh) 2001-01-24
SK283080B6 (sk) 2003-02-04
DE69803689T2 (de) 2002-10-10
HUP0102086A2 (hu) 2001-12-28
CZ290679B6 (cs) 2002-09-11
CA2305468A1 (en) 1999-04-22
IL135520A0 (en) 2001-05-20
IL135520A (en) 2007-07-24
NO20001810D0 (no) 2000-04-07
KR20010015717A (ko) 2001-02-26
DE69803689D1 (de) 2002-03-14
EP1021442B1 (fr) 2002-01-30
PT1021442E (pt) 2002-06-28
JP2001519431A (ja) 2001-10-23
EE200000207A (et) 2001-04-16
RU2203281C2 (ru) 2003-04-27
WO1999019325A1 (fr) 1999-04-22

Similar Documents

Publication Publication Date Title
EP1278741B1 (en) Muscarinic agonists
RU2095360C1 (ru) Производные индола, их оптические изомеры и фармацевтически приемлемые соли
US5077293A (en) 1-indolyalkyl-4-(alkoxypyrimidinyl)piperazines
JP3157839B2 (ja) 融合トロパン誘導体、それらの製造及び使用
JPH08333363A (ja) インドール誘導体
EP0624156A1 (en) Isatin derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same
JPH07206818A (ja) インドリルシクロアルカニルアミン抗偏頭痛剤
AU639301B2 (en) New centrally acting 6,7,8,9-tetrahydro-3h-benz(e)indole heterocyclics
US5391549A (en) Cinnoline-3-carboxylic acid derivatives
JPH07121943B2 (ja) ５−ｈｔ１アゴニストとしてのインドール誘導体
JP4505135B2 (ja) Ｄ２及びｄ３ドーパミンならびに５ｈｔ１ａ及び５ｈｔ２セロトニンのレセプターのリガンドとしての８−アザビシクロ［３．２．１］オクタン−３−メタンアミン誘導体
JP2003517481A (ja) 抗精神病複素環式化合物
JPH0733744A (ja) インダゾール誘導体およびその塩
JP2002534427A (ja) ３，４−ジヒドロ−２ｈ−ベンゾ［１，４］オキサジニル−メチル［３−（１ｈ−インドール−３−イル）−アルキル］−アミン
TW209219B (no)
KR20000005392A (ko) 3-(1,2,3,4-테트라히드로이소퀴놀린-2-일)메티래-8-아자비시클록3.2.1옥탄 유도체, 그 제조 및 치료학적 적용2
MXPA00003414A (en) 8-azabicyclo [3.2.1]octane-3-methanamine derivatives as ligands of d2 and d3 dopamine and 5ht1a and 5ht2 serotonin receptors
TW219937B (no)
EP1535912A1 (en) Muscarinic agonists
JPH01228969A (ja) ベンゾ〔６，７〕シクロヘプタ〔１，２−ｃ〕ピリダジン化合物およびその医薬用途

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050926

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090317

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090608

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090615

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090917

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091027

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100125

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100420

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100426

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130430

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees